{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:32:25Z","timestamp":1782570745294,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":39,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.humpath.2025.105788","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T16:52:36Z","timestamp":1746809556000},"page":"105788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Plasmacytoid urothelial carcinoma of the urinary bladder: A single institution experience with focus on next-generation sequencing (NGS) and PD-L1 immunohistochemistry"],"prefix":"10.1016","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0099-7499","authenticated-orcid":false,"given":"Dimitrios","family":"Korentzelos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Diamantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maedeh","family":"Mohebnasab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Dhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela M.","family":"Quiroga-Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.humpath.2025.105788_bib1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/ajcp\/aqx029","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 49 cases","volume":"147","author":"Fox","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2025.105788_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.humpath.2019.04.012","article-title":"Plasmacytoid\/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients","volume":"90","author":"Perrino","year":"2019","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105788_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/his.13752","article-title":"Variants and new entities of bladder cancer","volume":"74","author":"Lopez-Beltran","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2025.105788_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2024.04.012","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases","volume":"148","author":"Zheng","year":"2024","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105788_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/BLC-190258","article-title":"Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes","volume":"6","author":"Diamantopoulos","year":"2020","journal-title":"Bladder Cancer"},{"issue":"4","key":"10.1016\/j.humpath.2025.105788_bib6","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng.3503","article-title":"Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer","volume":"48","author":"Al-Ahmadie","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2025.105788_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2018.10.033","article-title":"Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations","volume":"85","author":"Palsgrove","year":"2019","journal-title":"Hum Pathol"},{"issue":"7492","key":"10.1016\/j.humpath.2025.105788_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.humpath.2025.105788_bib9","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-Invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.humpath.2025.105788_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100424","article-title":"Characterizing the genomic landscape of the micropapillary subtype of urothelial carcinoma of the bladder harboring activating extracellular mutations of ERBB2","volume":"37","author":"Posada","year":"2024","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105788_bib11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2025.105788_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2013.00086","article-title":"Activating mutations in ERBB2 and their impact on diagnostics and treatment","volume":"3","author":"Herter-Sprie","year":"2013","journal-title":"Front Oncol"},{"issue":"17","key":"10.1016\/j.humpath.2025.105788_bib13","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-16-2191","article-title":"HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2(+) breast cancer","volume":"23","author":"Xu","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.humpath.2025.105788_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.humpath.2025.105788_bib15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.humpath.2025.105788_bib16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.humpath.2025.105788_bib17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.humpath.2025.105788_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41588-020-00752-4","article-title":"The association between tumor mutational burden and prognosis is dependent on treatment context","volume":"53","author":"Valero","year":"2021","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.humpath.2025.105788_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","article-title":"Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase","volume":"7","author":"Valero","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.humpath.2025.105788_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020411","article-title":"Immune-checkpoint inhibitors in advanced bladder cancer: seize the day","volume":"10","author":"Maiorano","year":"2022","journal-title":"Biomedicines"},{"issue":"25","key":"10.1016\/j.humpath.2025.105788_bib21","first-page":"2483","volume":"383","author":"Powles","year":"2020","journal-title":"Avelumab Maintenance for Urothelial Carcinoma. Reply. N Engl J Med"},{"issue":"3","key":"10.1016\/j.humpath.2025.105788_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1215","article-title":"Significance of PD-L1 in metastatic urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"7","author":"Maiorano","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.humpath.2025.105788_bib23","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1097\/PAS.0000000000000922","article-title":"Immunohistochemical differentiation of plasmacytoid urothelial carcinoma from secondary carcinoma involvement of the bladder","volume":"41","author":"Borhan","year":"2017","journal-title":"Am J Surg Pathol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725000759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725000759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T17:15:00Z","timestamp":1748020500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817725000759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":23,"alternative-id":["S0046817725000759"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105788","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasmacytoid urothelial carcinoma of the urinary bladder: A single institution experience with focus on next-generation sequencing (NGS) and PD-L1 immunohistochemistry","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105788"}}